SLC5A2 and type 2 diabetes mellitus: On a separate note, even though the development of selective SGLT2 inhibitors (SGLT2i) has been a priority for reasons previously explained, it is worth mentioning that a dual SGLT1 and SGLT2 inhibitor by the name of sotagliflozin has, in recent years, been approved for the treatment of both T1DM and T2DM [22].